We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ORPHAN DRUGS STRAINING RESOURCES FOR UK'S NHS

ORPHAN DRUGS STRAINING RESOURCES FOR UK'S NHS

November 7, 2005

The growing use of orphan drugs -- medications used to treat rare diseases and conditions -- by UK healthcare provider the National Health Service (NHS) is straining budgets, according to two new articles published in the British Medical Journal.

Orphan drugs are often expensive and are of little overall benefit as they only treat a very small number of patients. In the past, the NHS has been willing to pay for orphan drugs as they have been used only rarely and the effect on the total budget has been negligible. However, as more orphan drugs become available, the impact on NHS spending is growing, and some industry sources are calling for the NHS to stop providing them.

Critics of such action have stressed that a person's health should not be considered of less value purely because the condition they are suffering from is rare. They go on to state that by giving orphan drugs a special status in NHS funding they are avoiding potentially difficult and unpopular decisions in the future.

However, industry sources claim that a nation-wide commitment to provide orphan drugs will mean that resources will be over-stretched and that patients with more common diseases will pay the cost, suffering from reduced access to cheap and effective drugs.

The UK is currently trying to reduce its drug spending, which stands at around US$417.6 per capita. Pharmaceutical prices are among the highest in Europe and new measures have included imposing a mandatory 7% price reduction for all drugmakers with sales to the NHS of over GBP1mn (US$1.75mn).

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Vaccine needle

    Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

  • Luminex logo

    Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

  • Acquires -Acquired

    Amgen to Buy Five Prime Therapeutics for $1.9 Billion

  • abbott-logo.gif

    Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing